10
Participants
Start Date
February 28, 2022
Primary Completion Date
May 31, 2024
Study Completion Date
May 31, 2024
AST-301(pNGVL3-hICD)
Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
rhuGM-CSF
Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
Placebo
Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
Pembrolizumab
Q3W; IV infusion
Capecitabine
On days 1-14 (Q3W), BID ; Oral administration,
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
China Medical University Hospital, Taichung
Changhua Christian Hospital, Changhua
Chi Mei Medical Center, Tainan City
Koo Foundation Sun Yat-Sen Cancer Center, Taipei
Moffitt Cancer Center, Tampa
The Ohio State University Comprehensive Cancer Center, Columbus
Toledo Clinic Cancer Center, Toledo
Gabrail Cancer Center Research, Canton
University of Illinois Cancer Center, Chicago
Nebraska Cancer Specialist, Omaha
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Ironwood Cancer and Research Centers, Chandler
Scripps Health, La Jolla
Providence Cancer Institute, Portland
University of Washington, Seattle
Lead Sponsor
Aston Sci. Inc.
INDUSTRY